Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer

  1. Yixiao Zhang
  2. Lisha Sun  Is a corresponding author
  3. Haonan Li
  4. Liping Ai
  5. Qingtian Ma
  6. Xinbo Qiao
  7. Jie Yang
  8. Hao Zhang
  9. Xunyan Ou
  10. Yining Wang
  11. Guanglei Chen
  12. Jinqi Xue
  13. Xudong Zhu
  14. Yu Zhao
  15. Yongliang Yang  Is a corresponding author
  16. Caigang Liu  Is a corresponding author
  1. Shengjing Hospital of China Medical University, China
  2. Dalian University of Technology, China
  3. Mayo Clinic, United States

Abstract

Background: Integrin family are known as key gears in focal adhesion for triple-negative breast cancer (TNBC) metastasis. However, the integrin independent factor TLN1 remains vague in TNBC.

Methods: Bioinformatics analysis was performed based on TCGA database and Shengjing Hospital cohort. Western blot and RT-PCR were used to detect the expression of TLN1 and integrin pathway in cells. A small-molecule C67399 was screened for blocking TLN1 and integrin β1 through a novel computational screening approach by targeting the protein-protein binding interface. Drug pharmacodynamics were determined through xenograft assay.

Results: Upregulation of TLN1 in TNBC samples correlates with metastasis and worse prognosis. Silencing TLN1 in TNBC cells significantly attenuated the migration of tumour cells through interfering the dynamic formation of focal adhesion with integrin β1, thus regulating FAK-AKT signal pathway and epithelial-mesenchymal transformation. Targeting the binding between TLN1 and integrin β1 by C67399 could repress metastasis of TNBC.

Conclusions: TLN1 overexpression contributes to TNBC metastasis and C67399 targeting TLN1 may hold promise for TNBC treatment.

Funding: This study was supported by grants from the National Natural Science Foundation of China (No. 81872159, 81902607, 81874301), Liaoning Colleges Innovative Talent Support Program (Name: Cancer Stem Cell Origin and Biological Behaviour), Outstanding Scientific Fund of Shengjing Hospital (201803) and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Yixiao Zhang

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  2. Lisha Sun

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    For correspondence
    sunlisha1224@126.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4095-5026
  3. Haonan Li

    School of Bioengineering, Dalian University of Technology, Dalian, China
    Competing interests
    No competing interests declared.
  4. Liping Ai

    Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  5. Qingtian Ma

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  6. Xinbo Qiao

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6759-921X
  7. Jie Yang

    Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  8. Hao Zhang

    Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  9. Xunyan Ou

    Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  10. Yining Wang

    Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  11. Guanglei Chen

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  12. Jinqi Xue

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  13. Xudong Zhu

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    Competing interests
    No competing interests declared.
  14. Yu Zhao

    Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, United States
    Competing interests
    No competing interests declared.
  15. Yongliang Yang

    School of Bioengineering, Dalian University of Technology, Dalian, China
    For correspondence
    everbright99@foxmail.com
    Competing interests
    No competing interests declared.
  16. Caigang Liu

    Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
    For correspondence
    angel-s205@163.com
    Competing interests
    Caigang Liu, Reviewing editor, eLife.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3729-2839

Funding

National Natural Science Foundation of China (81872159)

  • Caigang Liu

Liaoning Colleges Innovative Talent Support Program (Cancer Stem Cell Origin and Biological Behavior)

  • Caigang Liu

Outstanding Scientific Fund of Shengjing Hospital (201803)

  • Caigang Liu

Outstanding Young Scholars of Liaoning Province (2019-YQ-10)

  • Caigang Liu

National Natural Science Foundation of China (81902607)

  • Yixiao Zhang

National Natural Science Foundation of China (81874301)

  • Yongliang Yang

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: The current study was approved by the institutional research ethics committee of Shengjing Hospital of China Medical University (Project identification code: 2018PS304K, date on 03/05/2018), and each participant signed an informed consent before being included in the study. Meanwhile, this study was performed in very strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering of the animals, and all the animals were handled according to approved Animal Ethics and Experimentation Committee protocols of Shengjing Hospital of China Medical University (Project identification code: 2018PS312K, date on 03/05/2018).

Human subjects: Written informed consent was obtained from all the patients, and this study was approved by the institutional research ethics committee of China Medical University

Copyright

© 2022, Zhang et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,377
    views
  • 228
    downloads
  • 12
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yixiao Zhang
  2. Lisha Sun
  3. Haonan Li
  4. Liping Ai
  5. Qingtian Ma
  6. Xinbo Qiao
  7. Jie Yang
  8. Hao Zhang
  9. Xunyan Ou
  10. Yining Wang
  11. Guanglei Chen
  12. Jinqi Xue
  13. Xudong Zhu
  14. Yu Zhao
  15. Yongliang Yang
  16. Caigang Liu
(2022)
Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer
eLife 11:e68481.
https://doi.org/10.7554/eLife.68481

Share this article

https://doi.org/10.7554/eLife.68481

Further reading

    1. Medicine
    2. Neuroscience
    Emily M Adamic, Adam R Teed ... Sahib Khalsa
    Research Article

    Interactions between top-down attention and bottom-up visceral inputs are assumed to produce conscious perceptions of interoceptive states, and while each process has been independently associated with aberrant interoceptive symptomatology in psychiatric disorders, the neural substrates of this interface are unknown. We conducted a preregistered functional neuroimaging study of 46 individuals with anxiety, depression, and/or eating disorders (ADE) and 46 propensity-matched healthy comparisons (HC), comparing their neural activity across two interoceptive tasks differentially recruiting top-down or bottom-up processing within the same scan session. During an interoceptive attention task, top-down attention was voluntarily directed towards cardiorespiratory or visual signals. In contrast, during an interoceptive perturbation task, intravenous infusions of isoproterenol (a peripherally-acting beta-adrenergic receptor agonist) were administered in a double-blinded and placebo-controlled fashion to drive bottom-up cardiorespiratory sensations. Across both tasks, neural activation converged upon the insular cortex, localizing within the granular and ventral dysgranular subregions bilaterally. However, contrasting hemispheric differences emerged, with the ADE group exhibiting (relative to HCs) an asymmetric pattern of overlap in the left insula, with increased or decreased proportions of co-activated voxels within the left or right dysgranular insula, respectively. The ADE group also showed less agranular anterior insula activation during periods of bodily uncertainty (i.e. when anticipating possible isoproterenol-induced changes that never arrived). Finally, post-task changes in insula functional connectivity were associated with anxiety and depression severity. These findings confirm the dysgranular mid-insula as a key cortical interface where attention and prediction meet real-time bodily inputs, especially during heightened awareness of interoceptive states. Furthermore, the dysgranular mid-insula may indeed be a ‘locus of disruption’ for psychiatric disorders.

    1. Medicine
    Yanling Huang, Haocong Mo ... Geyang Xu
    Research Article

    Glucagon-like peptide 1 (GLP-1) is a gut-derived hormone secreted by intestinal L cells and vital for postprandial glycemic control. As open-type enteroendocrine cells, whether L cells can sense mechanical stimuli caused by chyme and thus regulate GLP-1 synthesis and secretion is unexplored. Molecular biology techniques revealed the expression of Piezo1 in intestinal L cells. Its level varied in different energy status and correlates with blood glucose and GLP-1 levels. Mice with L cell-specific loss of Piezo1 (Piezo1 IntL-CKO) exhibited impaired glucose tolerance, increased body weight, reduced GLP-1 production and decreased CaMKKβ/CaMKIV-mTORC1 signaling pathway under normal chow diet or high-fat diet. Activation of the intestinal Piezo1 by its agonist Yoda1 or intestinal bead implantation increased the synthesis and secretion of GLP-1, thus alleviated glucose intolerance in diet-induced-diabetic mice. Overexpression of Piezo1, Yoda1 treatment or stretching stimulated GLP-1 production and CaMKKβ/CaMKIV-mTORC1 signaling pathway, which could be abolished by knockdown or blockage of Piezo1 in primary cultured mouse L cells and STC-1 cells. These experimental results suggest a previously unknown regulatory mechanism for GLP-1 production in L cells, which could offer new insights into diabetes treatments.